MedTrace Logo

Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

NCT07233720 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2025-11-18

No results posted yet for this study

Summary

This is a prospective single arm, multi-center, real-world study to observe the efficacy and safety of ZR (Zanubrutinib combined with Rituximab) in the first-line treatment for patients with marginal zone lymphoma (MZL).

Conditions

Interventions

DRUG

Zanubrutinib

160mg twice daily continuous oral administration.

DRUG

Rituximab

375mg/m2, Intravenous administration on day 1 of each 3-week cycle

Sponsors & Collaborators

  • Henan Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Zhihua Yao, M.D. Ph.D · Henan Cancer Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-18
Primary Completion
2028-06-30
Completion
2030-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07233720 on ClinicalTrials.gov